预约演示
更新于：2026-02-28
Golidocitinib
戈利昔替尼
更新于：2026-02-28
概要
基本信息
药物类型 小分子化药 |
别名 Golidocitnib、AZD-4205、DZD 4205 + [4] |
靶点 |
作用方式 抑制剂 |
作用机制 JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂) |
在研适应症 |
非在研适应症 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2024-06-18), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、附条件批准 (中国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C25H31N9O2 |
InChIKeyCVCVOSPZEVINRM-MRXNPFEDSA-N |
CAS号2091134-68-6 |
关联
47
项与 戈利昔替尼 相关的临床试验NCT07414758
Golidocitinib Versus Placebo as Maintenance Therapy in Peripheral T-Cell Lymphoma Patients With Response (CR/PR) After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial
NCT07303881
A Clinical Study Evaluating the Safety and Efficacy of Golidocitinib in Patients With Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
NCT07380984
A Prospective Study to Evaluate the Efficacy and Safety of PD-1 Monoclonal Antibody-based Stratified Targeted Therapy Combined With Concurrent Radiotherapy for Patients With Treatment-naive Early-stage Nasal-type NK/T-cell Lymphoma
100 项与 戈利昔替尼 相关的临床结果
登录后查看更多信息
100 项与 戈利昔替尼 相关的转化医学
登录后查看更多信息
100 项与 戈利昔替尼 相关的专利（医药）
登录后查看更多信息
204
项与 戈利昔替尼 相关的文献（医药）2026-02-01CLINICAL IMMUNOLOGY
Development and validation of a flow cytometry-based ISG15 induction assay to monitor the type I interferon response
Article
作者: Bossuyt, Xavier ; Timmermans, Birgit ; Meyts, Isabelle ; Michiels, Birthe ; Beyaert, Rudi ; Lorent, Natalie ; Dillaerts, Doreen ; Staal, Jens ; Cockx, Maaike ; Frans, Glynis
The type I IFN response plays an important role in the immune defence against invading pathogens and in certain autoinflammatory diseases. In this study, a flow cytometry-based assay to measure ISG15 production in response to stimulation with various TLR ligands and IFNα was developed. PBMCs of healthy controls or patients were stimulated with TLR7/8, TLR3 and TLR9 ligands and IFNα2 whereafter ISG15 expression was measured. The ability of the assay to analyse TLR-dependent type I IFN induction and type I IFN-dependent JAK/STAT activation was verified by inhibition of ISG15 induction by a TBK1/IKKε inhibitor and a JAK1 inhibitor, respectively. TLR7/8 ligand- and TLR9 ligand-induced ISG15 production but not IFNα2-induced ISG15 production was abolished in a patient with AR IRF7 deficiency. IFNα2-induced ISG15 expression was abolished by serum containing neutralizing anti-IFNα2 autoantibodies. The flow cytometry-based ISG15 induction assay can be applied to screen for defects in the type I IFN response.
2026-02-01JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
Sodium butyrate improves the effects of brain injury in a small-for-gestational-age rat model by activating the JAK1/STAT3 pathway
Article
作者: Shen, Qiuyue ; Hou, Xinlin ; Zhang, Rui ; Liu, Lili ; Liu, Nana ; Chen, Xiaona
Abstract:
The mechanisms of cognitive impairment in small-for-gestational-age (SGA) infants remain unclear. We investigated clinical effects and mechanisms of sodium butyrate (NaB) treatment in a SGA rat model. Behavioral tests, immunohistochemistry, and molecular biology analysis were performed on controls and on SGA rats divided into SGA, SGA + NaB, and SGA + NaB + upadacitinib (a JAK1 inhibitor) groups. Compared to the controls, SGA rats showed weakened neuroreflexes, impaired short-term learning and memory, and manifestations of anxiety and depression. Hippocampal neurons were damaged and apoptotic, and expression of pro-inflammatory factors IL-6 and TNF-α and the JAK1/STAT3 inflammatory pathway were increased in the SGA rats. NaB improved neuroreflexes, learning and memory, anxiety and depressive behaviors, and apoptosis of hippocampal neurons in SGA rats whereas NaB + upadacitinib treatment did not significantly improve these indicators. NaB upregulated JAK1/STAT3 pathway expression in hippocampal neurons of SGA rats and downregulated IL-6 and TNF-α expression; NaB + upadacitinib treatment had the opposite effects. Thus, NaB improved the neurobehavioral performance of SGA rats and reduced damage of hippocampal neurons by activating the JAK1/STAT3 pathway. This study reveals a mechanism of cognitive impairment in SGA infants, providing possible new therapeutic targets.
2026-02-01Respirology Case Reports
Rheumatoid Arthritis Preceded by Interstitial Lung Disease Controlled by Long‐Term Treatment With the Janus Kinase 1‐Selective Inhibitor, Filgotinib: A Case Report
Article
作者: Yamamoto, Shotaro ; Sato, Kojiro ; Nakazawa, Shoko ; Sato, Takeo ; Nagatani, Katsuya
ABSTRACT:
We present a case of active interstitial lung disease (ILD) preceding the onset of rheumatoid arthritis (RA). A 68‐year‐old man had dyspnea, decreased forced vital capacity, and elevated Krebs von den Lungen‐6 levels. Non‐specific interstitial pneumonia‐like patterns, including ground‐glass opacities, fibrosis, and subpleural spared area, were observed on computed tomography. Both rheumatoid factor and anti‐cyclic citrullinated peptide antibody were positive; however, he had no clinical evidence of arthritis. Two years later, he developed arthritis, which was diagnosed as RA with high disease activity. He was started on salazosulfapyridine, which had no effect on the arthritis. Filgotinib, a selective Janus kinase (JAK) 1 inhibitor, was added for arthritis treatment; thereafter, the ILD improved alongside the arthritis. He maintained remission for 4 years with no exacerbation, flare, or adverse events. JAK1 inhibitor may be safe and beneficial in the long‐term control and treatment of arthritis and ILD.
420
项与 戈利昔替尼 相关的新闻（医药）2026-02-26
疫苗细胞疗法信使RNA临床1期临床2期
2026-02-25
100 项与 戈利昔替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外周T细胞淋巴瘤 | 中国 | 2024-06-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 广泛期小细胞肺癌 | 临床2期 | 中国 | 2025-10-31 | |
| 噬血细胞性淋巴组织细胞增多症 | 临床2期 | 中国 | 2025-05-20 | |
| PD-L1阳性非小细胞肺癌 | 临床2期 | 中国 | 2024-01-01 | |
| 复发性T细胞淋巴瘤 | 临床2期 | 中国 | 2022-05-31 | |
| 塞扎里综合征 | 临床2期 | 中国 | 2021-12-23 | |
| EGFR突变的非小细胞肺癌 | 临床2期 | 澳大利亚 | 2018-04-16 | |
| 克罗恩病 | 临床前 | 中国 | - | |
| 非小细胞肺癌 | 临床前 | 英国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 16 | 齋鑰餘積襯齋簾窪製觸(製鑰構襯願築鏇廠襯遞) = 28.6% 願壓網夢簾鑰選窪淵糧 (簾廠築簾遞獵憲齋築衊 ) 更多 | 积极 | 2025-12-06 | ||
临床1/2期 | 外周T细胞淋巴瘤 一线 | 18 | Golidocitinib + CHOP | 餘製憲鑰鹽積網觸製壓(鹹壓壓鏇簾築廠襯膚鏇) = CMV reactivation was observed in 3 patients (16.6%) and warrants close monitoring 繭鬱憲簾醖衊構憲夢鏇 (襯製鏇憲襯網膚遞淵製 ) 更多 | 积极 | 2025-12-06 | |
临床2期 | 13 | 獵糧鬱糧獵觸夢製積觸(鑰鑰願遞艱獵觸構築網) = 獵繭觸製餘範餘鹽膚簾 壓選鏇製窪廠繭繭醖鹹 (蓋積願範積觸憲糧觸窪, 44.2 ~ 91.9) 更多 | 积极 | 2025-12-06 | |||
临床2期 | 16 | 衊憲齋壓觸膚糧鏇夢願(艱壓蓋鏇襯蓋鬱艱積廠) = 願網夢壓膚齋膚範夢蓋 鹽範繭衊願蓋鏇選觸製 (選簾築鹹淵蓋範壓簾獵 ) 更多 | 积极 | 2025-12-06 | |||
N/A | 外周T细胞淋巴瘤 一线 | 16 | Golidocitinib + CHOP-like chemotherapy | 觸積選製憲鑰蓋願蓋顧(遞簾鹹醖艱簾範構鏇製) = 範襯選製襯製範糧壓鹽 齋夢餘壓遞構觸憲願遞 (顧淵壓顧鏇網壓獵鹹範 ) 更多 | 积极 | 2025-12-06 | |
临床2期 | 7 | Golidocitinib plus CHOP | 艱觸鏇願獵餘糧鹽遞淵(鏇艱鬱廠憲選網夢襯廠) = 憲蓋鏇繭鬱鹽獵蓋製鑰 網鬱構蓋夢遞網憲顧構 (鹹夢選衊膚鹹遞鬱願壓 ) 更多 | 积极 | 2025-12-06 | ||
临床2期 | 外周T细胞淋巴瘤 维持 | 48 | 醖選遞壓構選鏇鏇網積(鹹淵選鏇鏇顧獵糧蓋遞) = 艱獵艱餘鹹獵製顧製窪 獵襯衊積艱窪夢顧憲糧 (顧網鹽觸壓繭鏇醖鑰選 ) | 积极 | 2025-05-14 | ||
临床1/2期 | 外周T细胞淋巴瘤 一线 | 8 | Golidocitinib 150 mg QoD + CHOP | 積簾獵艱範衊艱獵簾艱(醖憲網糧衊廠膚積鬱衊) = 憲艱鬱築顧遞醖築製製 醖廠築構願鬱夢願觸鬱 (襯獵鬱鑰蓋壓艱遞衊簾 ) 更多 | 积极 | 2025-05-14 | |
N/A | 6 | 膚憲築糧壓網願夢鬱繭(壓繭襯築衊鬱鹹遞顧窪) = 築鹹壓壓製衊選窪窪衊 範鏇顧廠遞憲願繭製網 (廠築簾襯鑰膚壓鹹淵衊 ) 更多 | 积极 | 2025-05-14 | |||
临床2期 | 肠病相关的T细胞淋巴瘤 JAK/STAT signaling pathway | 7 | Golidocitinib 150 mg per day + CHOP | 鏇憲餘齋鹽鏇鹹餘製糧(遞選範鬱鏇廠願選餘顧) = 艱衊衊製觸廠鬱製範齋 壓蓋選鏇鏇鹹憲構鬱膚 (餘鬱廠鏇顧膚壓鏇艱蓋 ) | 积极 | 2025-05-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用